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Abstract
RET rearrangement is a newly identiﬁed oncogenic mutation
in lung adenocarcinoma (LADC). Activity of dovitinib
(TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in
RET-rearranged LADC has not been reported. The aims of the
study are to explore antitumor effects and mechanisms of
acquired resistance of dovitinib in RET-rearranged LADC. Using
structural modeling and in vitro analysis, we demonstrated that
dovitinib induced cell-cycle arrest at G0–G1 phase and apopto-
sis by selective inhibition of RET kinase activity and ERK1/2
signaling in RET-rearranged LC-2/ad cells. Strong antitumor
effect of dovitinib was observed in an LC-2/ad tumor xenograft
model. To identify the acquired resistance mechanisms to
dovitinib, LC-2/ad cells were exposed to increasing concentra-
tions of dovitinib to generate LC-2/ad DR cells. Gene-set
enrichment analysis of gene expression and phosphor-kinase
revealed that Src, a central gene in focal adhesion, was activated
in LC-2/ad DR cells. Saracatinib, an src kinase inhibitor, sup-
pressed ERK1/2 phosphorylation and growth of LC-2/ad DR
cells. Taken together, these ﬁndings suggest that dovitinib can
be a potential therapeutic option for RET-rearranged LADC, in
which acquired resistance to dovitinib can be overcome by
targeting Src. Mol Cancer Ther; 14(10); 2238–48. 2015 AACR.
Introduction
Lung cancer is the most common cause of cancer death world-
wide (1). Although survival of lung cancer patients still remains
poor, molecular targeted therapies, which block important onco-
genic pathways, have made remarkable progress over the years,
particularly in lung adenocarcinoma (LADC), which is the most
common histologic subtype of lung cancer (2–4). Indeed, treat-
ment with geﬁtinib or crizotinib in EGFR mutation–positive or
ALK-rearranged advanced LADC, respectively, has led to unprec-
edented improvements in objective response rate and progres-
sion-free survival over cytotoxic chemotherapy (5). The prevailing
concept of genomics-driven medicine based on remarkable efﬁ-
cacy of these targeted therapies and the expanding genomic
landscape of LADC have led to a signiﬁcant surge in the number
of genotype-directed lung cancer trials in molecular subtypes
deﬁned by oncogenic driver mutations in PIK3CA, HER2, BRAF,
and ROS1 (1).
RET encodes the tyrosine kinase receptor of growth factors
belonging to the glial-derived neurotrophic factor family. Recent-
ly, RET rearrangement, speciﬁcally fusion, has emerged as a new
molecular subtype in LADC (6, 7). The prevalence of RET fusions
has been estimated approximately 1.2% to 2.0% in LADC (6–11).
Several RET fusions have been identiﬁed in LADC, including
kinesin family member 5B (KIF5B)-RET, coiled-coil domain
containing 6 (CCDC6)-RET, tripartite motif-containing 33
(TRIM33)-RET, and nuclear receptor coactivator 4 (NCOA4)-RET.
Among all fusion variants, KIF5B–RET is the most common type
of fusion involving RET, present in approximately 90% of cases
reported to date (11). RET fusion was mutually exclusive with
other oncogenic driver mutations, such as EGFR, HER2, BRAF, or
EML4–ALK fusion (10–13). Furthermore, expression of exoge-
nous KIF5B–RET induced morphologic transformation and
anchorage-independent growth of NIH3T3 ﬁbroblasts (7). These
ﬁndings strongly suggest that targeted inhibition ofREToncogene
might be a potential strategy in the treatment of RET fusion–
positive LADC.
Small-molecule tyrosine kinase inhibitors (TKI), including
vandetanib, sunitinib, and sorafenib, effectively inhibited RET
fusion–positive LADC in preclinical models (7, 8, 10, 14, 15).
Therefore, several clinical trials of RET inhibitors are ongoing in
RET fusion–positive LADC. Recently, treatment of cabozantinib
and vandetanib, which have RET inhibitory activity, resulted in
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dramatic responses in patients with RET fusion–positive LADC
(12, 16).
Dovitinib (TKI258) is a potent inhibitor of receptor tyrosine
kinases, including ﬁbroblast growth factor receptor (FGFR) 1–3,
VEGFR 1–3, platelet-derived growth factor receptor (PDGFR)-b,
which has shown antitumor and antiangiogenic effects in pre-
clinicalmodels of colon, breast, bladder, pancreatic, and renal cell
cancers (17–19).However, antitumor activity of dovitinib inRET-
rearranged LADC has not been reported, except for the fact that
dovitinib inhibits the RET kinase at a range of 7 nmol/L in an
in vitro kinase assay (ref: dovitinib investigator's brochure).
Herein, we show potent antitumor activity of dovitinib in
preclinical models of RET-rearranged LADC. In addition, we
report the mechanism of acquired resistance to dovitinib in
RET-rearranged LADC.
Materials and Methods
Compounds, antibodies, and cell lines
Dovitinib was kindly provided by Novartis Institutes for Bio-
medical Research (Basel, Switzerland). Geﬁtinib, vandetanib,
sorafenib, sunitinib, saracatinib, and PF-562,271 were purchased
from Selleck Chemicals.
Antibodies against EGFR, p-EGFR, RET, p-RET (Y905), AKT,
p-AKT (S473), ERK1/2, p-ERK1/2 (T202/Y204), Cyclin D1, p21,
p27, FAK, p-FAK (Y397), Src, p-Src (Y416), PDGFRb, c-KIT, FGFR3
and integrin b1, integrin b3, integrin b4, integrin b5, integrin a4,
integrin a5 were purchased from Cell Signaling Technology.
Rabbit polyclonal antibody to RET (p-Y1062; ab51103), p-FLT3
(Y589; ab171975) was purchased from Abcam. Anti-b-actin anti-
body was purchased from Sigma Aldrich.
LC-2/ad cells were obtained from RIKEN in September 2013,
NCI-H1299 cells and HEK293 cells were obtained from ATCC in
January 2013. Each cell line was cultured using the medium
recommended by the suppliers and never cultured for more than
3 months. The cell lines have not been authenticated by the
authors.
Plasmid constructs and transfection
The plasmids that express KIF5B–RET, CCDC6–RET, and KRAS
G12Vwere purchased fromAddgene. HEK293 cells were plated at
a density of 0.5  105 per 60 mm dish 1 day before transfection.
HEK293 cells were transfected with the appropriate expression
plasmids using Polyjet transfection reagent (SignaGen), accord-
ing to the manufacturer's instructions. Transfected HEK293 cells
were cultured at 37C for 24 hours and then treated with or
without dovitinib for an additional 4 hours prior to lysis.
In silico modeling
The structure models of RET with dovitinib, sunitinib, and
vandetanib were modeled by Glide version 5.8 (Schr€odinger). All
ﬁgures were drawn using PyMol software (Schr€odinger).
Growth inhibition assay
For MTT assays, cultured cells were seeded into 96-well plates
(3,000 cells per well). Twenty-four hours after seeding, serial
dilutions of appropriate inhibitors were added to the culture.
After 72 hours, 50 mL ofMTT (5mg/mL stock solution)was added
and the plates were incubated for an additional 4 hours. The
mediumwas discarded and the formazan blue, whichwas formed
in the cells, was dissolved with 100 mL DMSO. The optical density
wasmeasured at 540nm.Relative survival in the presence of drugs
was normalized to DMSO control cells after background subtrac-
tion. For colony formation assays, cells were seeded into 6-well
plates (2.5  104 cells per well) and treated with the agents
indicated in RPMI1640 containing 10% FBS for 14 days. Com-
pound treatments were replaced at least every 3 days during the
assay. After 14 days, cells were ﬁxed in 3% paraformaldehyde in
PBS for 10 minutes at room temperature and stained with 0.5%
crystal violet in 20% methanol for 20 minutes. Images were
captured using ﬂatbed scanner, and the cells were dissolved with
20% acetic acids in 20% methanol for 30 minutes. Assays were
performed independently at least three times.
Apoptosis assay and cell-cycle assay
An apoptosis assay was performed using the Annexin V–FITC
Detection Kit (BD Biosciences) according to the manufacturer's
protocol. For the cell-cycle assay, 4.0  105 of LC-2/ad cells were
ﬁxed with cold-80% ethanol for 1 hour on ice. The cells were then
centrifuged at 800 rpm for 5minutes followed by resuspension in
1mL of PIMaster Mix containing 40 mL of propidium iodide (Life
Technologies), 10 mL of RNase A (Sigma-Aldrich) and 950 mL of
PBS. After incubation at 37C for 30 minutes, DNA ploidy was
analyzed by ﬂow cytometry.
Immunoblotting
Preparation of whole-cell protein lysates and Western blot
analysis were described previously. Brieﬂy, cells were then chilled
on ice, washed twice with ice-cold PBS, and lysed in a buffer (Cell
Signaling Technology) containing 1 mmol/L phenylmethylsufo-
nylﬂuoride and 1 protease inhibitors (Sigma Aldrich). Protein
concentrations were determined using a Bradford Assay kit (Bio-
Rad Laboratories). Equal amounts of protein in cell lysates were
separated by SDS-PAGE, transferred to membranes, immuno-
blotted with speciﬁc primary and secondary antibodies, and the
blot was detected by SuperSignal West Pico Chemiluminescent
Substrate (Thermo Fisher Scientiﬁc), according to the manufac-
turer's instructions.
siRNA transfection
siRNA was synthesized by Invitrogen (The sequence of siRNA
listed in Supplementary Table S2) and was transfected into the
cells using Lipofectamine RANiMAX (Invitrogen) according to the
manufacturer's instructions.
Human phospho-kinase array
The human phospho-kinase array kit (R&D Systems) was used
to detect the activation of 49 different protein kinases mediating
various aspects of cellular proliferation following the manufac-
turer's instructions. Brieﬂy, LC-2/ad cells and LC-2/ad DR cells
were plated in 10 cm dishes and cultured at 37C for 28 hours.
After cell lysis, 500 mg of lysate was applied to a membrane-
anchored phosphor-kinase array and incubated at 4C for 24
hours. Membranes were exposed to chemiluminescent reagents
and detected by X-ray ﬁlm (AGFA).
Establishment of dovitinib-resistant LC-2/ad cell line
LC-2/ad cells were cultured in increasing concentrations of
dovitinib up to 5 mmol/L to generate polyclonal-resistant clones
(LC-2/ad DR). After approximately 6 months, LC-2/ad DR cells
with strong resistance to dovitinib (IC50 > 3 mmol/L) were
established.
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Xenograft studies
All animal experiments were carried out under an Institutional
Animal Care and Use Committee–approved protocol and insti-
tutional guidelines for the proper and humane use of animals.
Nude mice were injected subcutaneously with 5  106 LC-2/ad
cells or LC-2/ad DR cells. Mice were randomized into groups of 7
animals and treated with either vehicle, vandetanib or dovitinib
(oral, every day) for the indicated duration of treatment. The
length,width, anddepthof the tumormassweremeasured every 2
days using calipers, and tumor volume was calculated as: tumor
volume ¼ 0.5236  length  width  depth (mm3). The rate of
change in body weight (BW) was calculated using the following
formula: BW¼W/W0100,whereWandW0 are the bodyweight
on a speciﬁc experimental day and on the ﬁrst day of treatment,
respectively.
Microarray analysis and gene-set enrichment analysis
Total RNA was extracted using RNeasy columns (Qiagen)
according to the manufacturer's protocol. Total RNA was ampli-
ﬁed and puriﬁed using Target Amp-Nano Labeling Kit for Illu-
mina Expression Bead Chip (EPICENTRE) to yield biotinylated
cRNA according to the manufacturer's instructions. We used
gene-set enrichment analysis (GSEA) to evaluate the genes com-
prising a speciﬁc gene signature are coordinately up- or down-
regulated between LC-2/ad and LC-2/ad DR cells. Gene signa-
tures queried included those deposited in C2 KEGG genesets
collection in the Molecular Signatures Database (MSigDB; ver-
sion 4.0; http://www.broadinstitute.org/gsea/msigdb/index.jsp).
A gene set of Focal adhesion factors used in the analysis was
constructed using 38 Focal adhesion core factors. The data
discussed in this publication have been deposited in NCBI's
Gene Expression Omnibus (20) and are accessible through GEO
series accession number GSE69226 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc¼GSE69226).
Statistical analysis
Quantitative results were analyzed by ANOVA or t test. Statis-
tical signiﬁcance was established for P < 0.05.
Results
Dovitinib inhibits RET kinase activity
Dovitinib, of which chemical structure was shown in Fig. 1A,
targets type III, IV, and V RTKs, including PDGFRb, CSF-1R,
KIT, FLT3, VEGFR, TrkA, RET, and FGFRs. To explore RET
fusion as an additional target indication of dovitinib, we ﬁrst
performed in silico modeling of RET with dovitinib and two
other RET–TKIs, sunitinib and vandetanib (Fig. 1B). Docking
score of RET kinase complex with dovitinib, sunitinib, and
vandetanib were calculated using Glide (Supplementary Table
S1 and Fig. 1B). Docking simulation showed almost identical
docking structure for dovitinib and two other RET–TKIs.
Dovitinib–RET complex exhibited high docking score
(9.16), which was comparable with those of sunitinib and
vandetanib. The structure modeling suggested that dovitinib
formed hydrogen bonds with A907 and Q905 sites, which are
located within active site of the RET kinase. According to
Novartis investigator's brochure, dovitinib inhibited RET in
nanomolar range (7 nmol/L) an in vitro kinase assay. Together,
these results strongly suggest that dovitinib has potential to
inhibit RET kinase activity.
To determine whether dovitinib could inhibit kinase activity
of the two most common type of fusions, CCDC6–RET and
KIF5B–RET, we ﬁrst transfected HEK293 cells with plasmids
encoding each fusion variants. Cells were lysed after dovitinib
treatment and exogenous expression of RET kinase tyrosine 905
(Y905) was determined by immunoblot analysis (Fig. 1C).
Dovitinib suppressed the phosphorylation of Y905 in both
CCDC6–RET and KIF5B–RET fusion kinases, resulting in sig-
niﬁcant reduction of ERK1/2 phosphorylation in CCDC6–RET
or KIF5B–RET plasmid-transfected HEK293 cells. However,
ERK1/2 phosphorylation was unaffected by dovitinib in
HEK293 cells transfected with mutant KRASG12V plasmids.
Next, we examined whether dovitinib selectively inhibited RET
activity, leading to decreased ERK1/2 phosphorylation, by
transfecting either KRASG12V or KIF5B–RET plasmids into
HEK293 cells (Fig. 1D). The ERK1/2 phosphorylation induced
by KRASG12V transfection could not be suppressed by treatment
with dovitinib, a RET–TKI (vandetanib) or a selective EGFR-TKI
(geﬁtinib). On the other hand, dovitinib and vandetanib, but
not geﬁtinib, potently inhibited phosphorylation of RET and
ERK1/2 in KIF5B–RET transfected HEK293 cells. Taken togeth-
er, these results indicate that dovitinib has ability to speciﬁcally
inhibits RET kinase activity and ERK1/2 signaling mediated
by RET.
Dovitinib induces cell-cycle arrest and apoptosis of
RET-rearranged LADC via selective inhibition of RET kinase
LC-2/ad cells were recently reported to harbor the CCDC6–
RET rearrangement. Silencing of RET expression by siRNA
targeting RET signiﬁcantly decreased phosphorylation of
ERK1/2, a key molecule of RET downstream signaling, and cell
viability in LC-2/ad cells (14, 15). These results indicate that
CCDC6–RET plays an important role in the proliferation and
survival of LC-2/ad cells.
Next, we evaluated the effect of dovitinib on the growth of the
LC-2/ad cells. Compared with H1299 cells without RET rear-
rangement, dovitinib potently suppressed the growth of LC-2/ad
(IC50 ¼ 0.2 mmol/L), indicating selective antitumor effects of
dovitinib against RET kinase activity (Fig. 2A). Consistentwith the
results of MTT assays, treatment of dovitinib suppressed the
phosphorylation of RET and ERK1/2 in a dose-dependentmanner
(Fig. 2B). Moreover, dovitinib inhibited the expression of cyclin
D1 and induced p21 (Fig. 2B), which was in parallel with the fact
that dovitinib signiﬁcantly induced cell-cycle arrest at G0–G1
phase (Fig. 2C). Furthermore, treatment of dovitinib signiﬁcantly
increased a subpopulation of the Annexin V–positive apoptotic
cells (Fig. 2D).
As dovitinib is known to target multiple tyrosine kinases, the
growth suppression effect of dovitinib in LC-2/ad may not be
due to selective inhibition of RET kinase. To rule out this
possibility, effects of dovitinib on other known targets were
assessed in immunoblotting. As shown in Supplementary Fig.
S1A, dovitinib inhibited RET phosphorylation at the dose of
0.01 mmol/L, whereas it did not affect FLT3 phosphorylation
even at 1 mmol/L. The phosphorylation of FGFR and PDGFRb
were not detected in LC-2/ad. Consistent with the immunoblot
analysis, the introduction of siRET in LC-2/ad signiﬁcantly
suppressed the proliferation, whereas siFGFR3, siPDGFRb,
siFLT3, and siKIT had no signiﬁcant effect on cell viability (Fig.
2E and F).
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Taken together, these results suggest that dovitinib induces
cell-cycle arrest and cellular apoptosis via selective inhibition of
RET kinase and its downstream signaling in lung cancer cells
harboring RET rearrangement.
Dovitinib inhibits growth of RET-rearranged LADC more
effectively than other RET–TKIs
We next compared antitumor effects of dovitinib with other
known RET–TKIs, such as vandetanib, sunitinib, and sorafenib,
using geﬁtinib, a selective EGFR–TKI, as a negative control. Contrary
to geﬁtinib, dovitinib suppressed 100% inhibition of RET phos-
phorylation at the dose of 1 mmol/L. This wasmore evident in long-
exposure blots (Fig. 3A). Moreover ERK1/2 and the expression of
cyclin D1 inhibited by dovitinib, as potently as other known RET–
TKIs (Fig. 3A). Notably, compared with other RET–TKIs, dovitinib
exerted the most potent inhibitory effects on the proliferation of
LC-2/ad cells in MTT assays (Fig. 3B). The superior antitumor
activity of dovitinib to vandetanib, sunitinib and sorafenib
in LC-2/ad cells became more evident through long-term
(14 days) colony formation assays (Fig. 3C). Taken together,
our data suggest that dovitinib inhibits growth of RET-rear-
ranged LADC at least as effectively as other known RET–TKIs.
Antitumor activity of dovitinib in LC-2/ad xenograft models
To evaluate antitumor activity of dovitinib in vivo, we
tested the effects of dovitinib and vandetanib on the growth
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Figure 1.
Inhibition of RET-fusion kinase activity
by dovitinib. A, chemical structure of
dovitinib. B, X-ray structure of
dovitinib with RET, sunitinib with RET,
and vandetanib with RET. C, effects of
dovitinib on the phosphorylation
levels of RET in HEK293 cells
expressing CCDC6–RET, KIF5B–RET,
or KRAS. Each transfected HEK293
cell was treated with DMSO () or
dovitinib 1 mmol/L (DO) for 4 hours.
The expression levels of indicated
protein levels were detected by
Western blot analysis using the
corresponding antibodies. D, Western
blot analysis showing the effect of
dovitinib (DO), vandetanib (VA), and
geﬁtnib (GE) on expression of
indicated proteins. Each transfected
cell was treated with 1 mmol/L of
indicated inhibitor for 4 hours.
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of LC-2/ad xenograft tumors established in nude mice. Mice
treated with dovitinib showed remarkable tumor regression at
all doses without signiﬁcant weight loss at 30 and 60 mg/kg
doses of dovitinib (Fig. 4A and Supplementary Fig. S2A).
Vandetanib at a dose of 50 mg/kg also produced similar
efﬁcacy, although mice were not tolerated well and experienced
signiﬁcant weight loss (Supplementary Fig. S2A). In waterfall
plots, the percent volume changes of the individual tumors
were greater in dovitinib treatment group compared with those
in vandetanib group, showing complete tumor regression
(100%) in 3 of 7 mice treated with two different doses of
dovitinib (Fig. 4B). Dovitinib suppressed phosphorylation of
RET and ERK1/2 relative to vehicle treatment, as assessed by
immunoblots and immunohistochemistry of tumor tissues
from the xenograft (Fig. 4C and D). Taken together, our
in vitro and in vivo ﬁndings conﬁrm that dovitinib is effective
against RET fusion–positive LADC.
Activation of Src mediates acquired resistance to dovitinib in
LC-2/ad DR cells
In most targeted agents, acquired resistance eventually
develops after an initial response (21). To identify potential
mechanisms of acquired resistance to dovitinib, we established
LC-2/ad DR cells with acquired resistance to dovitinib
by exposing LC-2/ad cells to increasing doses of dovitinib.
LC-2/ad DR cells showed strong resistance to dovitinib (IC50 >
3 mmol/L; Fig. 5A). Next, LC-2/ad and LC-2/ad DR cells were
subjected to genome-wide gene expression proﬁling using
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Figure 2.
Inhibition of RET fusion–driven tumors
by dovitinib. A, relative survival of
H1299 and LC-2/ad against dovitinib
after 72 hours treatedwith dovitinib. B,
Western blot analysis of CCDC6–RET,
ERK1/2, and cyclin D1, p21, and b-actin
in LC-2/ad cells after treated with
dovitinib (DO) for 4 hours. C, LC-2/ad
cells were treated with dovitinib 0.5
mmol/L (DO) for 24 or 48 hours. Cell-
cycle distribution was measured by
propidium iodide staining and
subsequent FACS analysis. Error bars,
mean  SEM (n ¼ 3).  , P < 0.01,
vehicle (DMSO) versus DO (dovitinib)
in both 24 and 48 hours. D, FACS
analysis via the Annexin V/PI double-
staining assaywas used to observe the
induction of apoptosis. After treating
with DMSO or dovitinib 0.5 mmol/L
(DO) for 72 hours, cells were stained
with Annexin V-FITC/PI double
staining. Error bars, mean  SEM
(n ¼ 3).  , P < 0.05, DMSO versus
dovitinib (DO). E, MTT assay of siCON,
siFGFR3, siPDGFRb, siFLT3, siKIT, or
siRET-transfected LC-2/ad cells.
Indicated siRNA-transfected LC-2/ad
cells were incubated for 72 hours
before treating with MTT solution. F,
colony formation assay of siCON,
siFGFR3, siPDGFRb, siFLT3, siKIT, or
siRET-transfected LC-2/ad cells.
Indicated siRNA-transfected LC-2/ad
cells were incubated for 14 days before
staining with crystal violet.
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cDNA microarray. GSEA against Kyoto Encyclopedia of Genes
and Genomes (KEGG) database showed that focal adhesion
pathway was signiﬁcantly enriched, with Src contributing
signiﬁcantly to the core enrichment, in LC-2/ad DR cells, as
compared with LC-2/ad cells (Fig. 5B). LC-2/ad DR cells
displayed higher phosphorylation level of Src and focal adhe-
sion kinase (FAK) in phospho-kinase array than LC-2/ad cells,
which was conﬁrmed by immunoblots (Fig. 5C and D).
Increased Src activation in LC-2/ad DR cells led to constitutive
ERK1/2 phosphorylation unresponsive to dovitinib treatment
(Fig. 5D). Interestingly, contrary to LC-2/ad cells, LC-2/ad DR
cells did not activate RET kinase any more, suggesting the loss
of addiction to RET fusion in these cells (Fig. 5D).
Previous studies have demonstrated that Src sits on the
signaling node mediating resistance to multiple anticancer
agents (22). The increased activation of Src led us to hypoth-
esize that Src activation directly mediated acquired resistance to
dovitinib in LC-2/ad DR cells. To test this hypothesis, we
inhibited Src activity using either saracatinib, a selective Src
inhibitor, or siRNA targeting Src (siSrc) in LC-2/ad DR cells.
Although dovitinib and other known RET–TKIs could not
inhibit tumor growth in colony formation assays, saracatinib
signiﬁcantly exerted growth inhibitory effects on LC-2/ad DR
cells (Fig. 6A). Furthermore, siSrc could efﬁciently inhibit
tumor growth only in LC-2/ad DR cells (Fig. 6B). On the other
hand, siRET could not inhibit tumor growth in LC-2/ad DR
cells, suggesting the minimal role of RET signaling in survival
of these cells (Fig. 6B). Consistent with cell viability data,
inhibition of RET kinase by dovitinib or siRET abrogated
ERK1/2 activity only in RET-dependent LC-2/ad cells, and
inhibition of Src by saracatinib or siSrc abrogated ERK1/2 activ-
ity only in Src-dependent LC-2/ad DR cells (Fig. 6C and D).
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for 14 days. All cells were ﬁxed,
stained with crystal violet (0.005%),
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Finally, concurrent inhibition of RET and Src signaling did not
show synergistic antitumor effect in LC-2/ad DR cells, further
supporting complete loss of dependence on RET signaling
for survival upon acquisition of acquired resistance to dovitinib
(Fig. 6E).
Given the activation of FAK and mRNA upregulation of
integrin, we hypothesized that FAK–integrin axis was involved
in the Src activation. To rule out this hypothesis, we used PF-
562,271, ATP-competitive reversible inhibitor of FAK. Unex-
pectedly, PF-562,271 had neither antiproliferation effect nor
inhibition of downstream ERK1/2 activation in LC-2/ad DR
cells (Supplementary Fig. S3A and S3B). Expressions of integ-
rins in LC-2/ad DR cells were similar with LC-2/ad cells (Sup-
plementary Fig. S3C).
Taken together, these data indicate an essential role of Src in
mediating the acquired resistance to dovitinib in RET fusion–
positive LADC.
Discussion
In our study, we evaluated and compared antitumor activity
of dovitinib in RET fusion–driven LADC models. Dovitinib
efﬁciently suppressed growth of RET-rearranged LADC in vitro
and in vivo by inhibiting autophosphorylation of RET and
was shown to be at least as efﬁcacious as other known RET–
TKIs, such as sorafenib, sunitinib, and vandetanib. Our data
provided the preclinical evidence supporting a rationale for
the clinical development of dovitinib in patients with RET
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Figure 4.
Antitumor activity of dovitinib against
RET fusion–driven tumors. A, mice
bearing LC-2/ad cells were treated
with vehicle only (Vehicle), dovitinib
(DO 30 mg/kg or 60 mg/kg), or
vandetanib (VA 50 mg/kg) for 32
days. Average percentage of change
in tumor volume relative to initial
tumor volume is shown. Error bars,
SEM.  , P < 0.0001 for vehicle
(vehicle) versus dovitinib 30 mg/kg
(DO 30 mg/kg) treatment group. B,
waterfall plots showing the percent
change in volume (relative to initial
tumor volume) for the individual
tumors in each treatment group.
Maximum regression tumors for each
group are indicated. C, mice bearing
LC-2/ad cells expressing CCDC6–RET
were orally administered a dose of
0 (Vehicle), 30 mg/kg, or 60 mg/kg
dovitinib (DO), and 50 mg/kg
vandetanib (VA). Tumors were
collected and lysed at 6 hours
postdosing. The expression levels of
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ERK, and b-actin were detected by
Western blot analysis using the
appropriate antibodies. D,
immunohistochemical (IHC) analysis
of LC-2/ad xenograft tumor samples.
Mice were orally administered a
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and tumors were stained with
indicated antibodies. Photos shown
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fusion–driven LADC. Furthermore, we found that increased
activation of Src mediated acquired resistance to dovitinib by
phosphorylating RET downstream effector ERK1/2 in RET
fusion–positive LADC.
Given that RET rearrangement is a druggable target in LADC,
a number of clinical trials have been designed to investigate the
therapeutic effects of multikinase inhibitors targeting RET, such
as vandetanib (trial registration ID: NCT01823068), sunitinib
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Figure 5.
Src hyperactivation in acquired dovitinib-resistant cells. A, MTT assay comparing cell proliferation of indicated parental LC-2/ad cells and their corresponding
acquired dovitinib-resistant LC-2/ad DR cells upon treatment with dovitnib for 72 hours. B, the GSEA demonstrating a signiﬁcant enrichment of the
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(NCT01829217), cabozantinib (NCT01639508), and lenvati-
nib (NCT01877083), in RET fusion–positive LADC. In a recent
report of preliminary efﬁcacy in patients with RET fusion–
positive LADC, cabozantinib, an inhibitor of MET, VEGFR and
RET, achieved partial responses in 2 patients and durable stable
disease in 1 patient (12). Vandetanib, an inhibitor of VEGFR,
EGFR, and RET, showed a dramatic response in a patients with
advanced RET fusion–positive LADC (16). Moreover, alectinib
(CH5424802), which has been known to be a selective inhib-
itor of ALK, showed antitumor activity against RET fusion–
driven LADC models by inhibiting oncogenic RET fusion sig-
naling (23). Our data support the inclusion of dovitinib in the
therapeutic armamentarium of targeted agents currently being
tested for RET fusion–positive LADC. On the basis of our in
vitro data, the lowest effective dose of dovitinib in LC-2/ad cells
was 0.1 mmol/L (Fig. 2A and B, Supplementary Fig. S1A), which
can be extrapolated to 48.25 ng/mL. In our study, dovitinib
showed signiﬁcant anti-tumor effect in the LC-2/ad xenograft at
the dose of 30 mg/kg dovitinib. The trough plasma concentra-
tion (Cmin) of 7 to 23 ng/mL (20–60 nmol/L) were observed in
vivowith 30 mg/kg dovitinib doses, and the corresponding Cmax
and AUC values ranged from 339 to 952 ng/mL and 5,540 to
9,670 h*ng/mL, respectively (18). Dovitinib showed pharma-
codynamics effect in this dose concentration range. This infor-
mation suggests that the corresponding plasma exposures were
adequate for substantial efﬁcacy in the LC-2/ad xenograft
model. Moreover, dovitinib has been evaluated in human
phase I studies and was shown to have Cmax 273  126 ng/
mL at steady state of recommended dose (500 mg, 5 days on, 2
days off; refs. 18, 24). These results suggest that preclinical
doses tested in our study can safely be achieved in patients with
RET-rearranged lung adenocarcinoma.
Targeted agents that exploit genetic vulnerabilities in human
cancers have now been clinically validated as effective cancer
therapies. However, clinical efﬁcacy of these agents is limited by
the rapid emergence of drug resistance, which remains a substan-
tial challenge to the clinical management of advanced cancers
(21, 25–28). To our knowledge, this is the ﬁrst report on the
mechanism of acquired resistance to the RET inhibitor describing
a link between Src-dependent survival signal activation and drug
resistance in RET fusion–positive LADC.
Src regulates many fundamental cellular processes, including
cell growth, differentiation, migration, and drug resistance
(22, 29–32). In our study, acquisition of acquired resistance
to dovitinib is attributable to the activation of a Src-driven
bypass signaling pathway. We observed marked activation and
expression of Src in LC-2/ad DR cells, as compared with the LC-
2/ad cells. The blockade of Src signaling by saracatinib or siSrc
resulted in the marked suppression of ERK1/2 phosphoryla-
tion, suggesting a dominant role of Src on ERK1/2 activation in
LC-2/ad DR cells. Consistent with these results, treatment with
saracatinib and siSrc dramatically suppressed cell growth in LC-
2/ad DR cells. The disappointing lack of synergy in the com-
bined treatment of dovitinib and saracatinib may be due to the
fact that survival of LC-2/ad DR cells no longer depend on the
activity of RET fusion kinase (Figs. 5D and 6E). Similar to our
ﬁndings, loss of addiction to mutant EGFR resulted in gain of
addiction to both HER2/HER3 and PI3K/Akt signaling to
acquire EGFR–TKI resistance (33).
Integrins are a family of adhesion receptors for extracellular
matrix (ECM) proteins, integrins can transduce biochemical
signals into the cell to regulate a variety of cellular functions,
including proliferation, migration, survival, and drug resis-
tance (34–37). Focal adhesion kinase (FAK) is a nonreceptor
tyrosine kinase that mediates integrin signaling pathways. Src
family of cytosolic protein tyrosine kinases function intimately
with FAK in integrin signaling pathways (38, 39). In our study,
FAK activity was increased in LC-2/ad DR cells (Fig. 5D). These
data also raise the question as to whether FAK could play an
important role in the enhanced Src activation, resulting in the
acquisition of dovitinib resistance in LC-2/ad DR cells. How-
ever, the inhibition of FAK activity using PF-562,271 could not
suppress the downstream ERK1/2 activation and LC-2/ad DR
cell growth (Supplementary Fig. S3A and S3B). As shown in
Supplementary Fig. S3C, protein levels of integrins in LC-2/ad
DR cells were similar with LC-2/ad cells and treatment of
intergrinb1 could not inhibit the cell growth in LC-2/ad DR
cells (data not shown). These data suggest that integrin-medi-
ated FAK activation may not be critically involved in acquired
resistance to dovitinib in LC-2/ad DR cell. Instead, Src, as a
common node downstream of multiple drug resistance path-
ways, might be activated by various signal inputs from speciﬁc
RTKs, nonreceptor tyrosine kinases, or loss of protein tyrosine
phosphatase activity (29, 31). Therefore, it remains to be
further studied what mediates the enhanced activity of Src.
In conclusion, our ﬁndings support that dovitinib warrants
further clinical evaluation in patients with RET-rearranged LADC,
and targeting Src signaling is effective in RET-rearranged LADC
with acquired resistance to dovitinib.
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